

ASX RELEASE

2 March 2018

Simplified access to medicinal cannabis in NSW

MMJ PhytoTech Limited (“**MMJ**”) welcomes today’s announcement by the NSW Government outlining plans to simplify access to medicinal cannabis for doctors and patients in NSW. A copy of that announcement is available at:

http://www.health.nsw.gov.au/news/Pages/20180302_00.aspx

The streamlined approval process will see NSW Health partner with the Commonwealth to require a single clinical assessment by the Therapeutic Goods Administration. This key change will eliminate duplication from the current approval process and substantially shorten the time between application and approval for doctors in NSW to prescribe medicinal cannabis to their patients.

This is an important proposed change given that MMJ’s largest investment, Harvest One Cannabis Inc. (TSX-V: HVT), currently supplies Satipharm CBD capsules to approved patients in Australia.

– ENDS –

For investor and media enquiries please contact:

Investor Enquiries:

Jason Conroy
Chief Executive Officer
info@mmjphytotech.com.au

Media Enquiries:

Sam Burns
Six Degrees Investor Relations
M: +61 400 164 067